Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06375239 · ClinicalTrials.gov registry record

Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration

A clinical trial of Retinitis Pigmentosa and Stargardt Disease, sponsored by Ray Therapeutics.

Recruiting
Registry status
120
Enrollment target
1
Study location

NCT06375239: Recruiting study of Retinitis Pigmentosa and Stargardt Disease, sponsored by Ray Therapeutics.

NCT06375239 is a study of Retinitis Pigmentosa and Stargardt Disease that is actively recruiting participants, run by Ray Therapeutics. The registered enrollment target is 120 participants, below the 258-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06375239, a study of Retinitis Pigmentosa and Stargardt Disease, is actively recruiting participants, sponsored by Ray Therapeutics.

RECRUITING
Registry status
120 participants
Enrollment target
1
Study location

Study Summary

The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision. The mission of the VRAI is to enable the highest quality, standardized efficacy testing of patients with visual impairment. The VRAI facilitates the development and refinement of existing endpoints specifically for testing patients with Low Vision.

Primary Outcome

Determining how many patients in the visual range 20/70 - HM (depending upon indication) can perform specific tests of visual function with a measurable score.

Conditions Studied

Retinitis Pigmentosa Stargardt Disease Retinal Dystrophies Choroideremia Stargardt Macular Dystrophy Geographic Atrophy from Age-related Macular Degeneration X-lined Retinoschisis

Study Locations (1)

California

  • Vision Research and Assessment Institute - Irvine

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2024-04-05
Est. Completion 2026-04-30
Ray Therapeutics

4 total trials

What NCT06375239 shows while recruiting

NCT06375239 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 258-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (53% lower).

The record links to 7 conditions, with Retinitis Pigmentosa appearing as the primary indexed condition, and to 0 interventions.

NCT06375239 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT06375239 about?

NCT06375239 is a clinical study titled "Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration". The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision. The mission of the VRAI is to enable the highest quality, standardized efficacy testing of patients with visual impairment. The...

What is the current status of trial NCT06375239?

This trial is currently recruiting. The enrollment target is 120 participants. The study started on 2024-04-05. Estimated completion is 2026-04-30.

What conditions does trial NCT06375239 study?

This clinical trial studies the following conditions: Retinitis Pigmentosa, Stargardt Disease, Retinal Dystrophies, Choroideremia, Stargardt Macular Dystrophy.

Who is sponsoring clinical trial NCT06375239?

This trial is sponsored by Ray Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06375239 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Retinitis Pigmentosa

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06375239's enrollment target sits among peer trials

120 10th of 37 higher than 28 of 37 other Retinitis Pigmentosa trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Retinitis Pigmentosa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01174108 · 120 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

  • NCT01627301 · 120 participants · NA

    Sympathetic Overactivity in Post-traumatic Stress Disorder

  • NCT02025023 · 120 participants · Phase 3

    Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

  • NCT02128906 · 120 participants · Phase 2

    Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06375239

Source: ClinicalTrials.gov NCT06375239, the US trial registry maintained by the National Library of Medicine. NCT06375239 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.